LEXX Quote, Financials, Valuation and Earnings

Edesa Biotech, Inc. has a net margin of -2178.51% compared to Lexaria Bioscience Corp.'s net margin of --. Lexaria Bioscience Corp.'s return on equity of -147.19% beat Edesa Biotech, Inc.'s return on equity of -77.48%.

Lexaria Bioscience Corp. has a consensus price target of $4.50, signalling upside risk potential of 727.51%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 628.48%. Given that Lexaria Bioscience Corp. has higher upside potential than Edesa Biotech, Inc., analysts believe Lexaria Bioscience Corp. is more attractive than Edesa Biotech, Inc..

Lexaria Bioscience Corp. has a beta of 0.628, which suggesting that the stock is 37.221% less volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.

Lexaria Bioscience Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexaria Bioscience Corp. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.

Lexaria Bioscience Corp. quarterly revenues are $174K, which are larger than Edesa Biotech, Inc. quarterly revenues of --. Lexaria Bioscience Corp.'s net income of -$2.7M is lower than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, Lexaria Bioscience Corp.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexaria Bioscience Corp. is 13.87x versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of -2178.51% compared to Lexaria Bioscience Corp.'s net margin of --. Lexaria Bioscience Corp.'s return on equity of -147.19% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

Lexaria Bioscience Corp. has a consensus price target of $4.50, signalling upside risk potential of 727.51%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.55 which suggests that it could grow by 525.74%. Given that Lexaria Bioscience Corp. has higher upside potential than Oncolytics Biotech, Inc., analysts believe Lexaria Bioscience Corp. is more attractive than Oncolytics Biotech, Inc..

Lexaria Bioscience Corp. has a beta of 0.628, which suggesting that the stock is 37.221% less volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.

Lexaria Bioscience Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexaria Bioscience Corp. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

Lexaria Bioscience Corp. quarterly revenues are $174K, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. Lexaria Bioscience Corp.'s net income of -$2.7M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Lexaria Bioscience Corp.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexaria Bioscience Corp. is 13.87x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

ProMIS Neurosciences, Inc. has a net margin of -2178.51% compared to Lexaria Bioscience Corp.'s net margin of --. Lexaria Bioscience Corp.'s return on equity of -147.19% beat ProMIS Neurosciences, Inc.'s return on equity of -348.3%.

Lexaria Bioscience Corp. has a consensus price target of $4.50, signalling upside risk potential of 727.51%. On the other hand ProMIS Neurosciences, Inc. has an analysts' consensus of $105.58 which suggests that it could grow by 1410.47%. Given that ProMIS Neurosciences, Inc. has higher upside potential than Lexaria Bioscience Corp., analysts believe ProMIS Neurosciences, Inc. is more attractive than Lexaria Bioscience Corp..

Lexaria Bioscience Corp. has a beta of 0.628, which suggesting that the stock is 37.221% less volatile than S&P 500. In comparison ProMIS Neurosciences, Inc. has a beta of -0.050, suggesting its less volatile than the S&P 500 by 105.015%.

Lexaria Bioscience Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProMIS Neurosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexaria Bioscience Corp. pays -- of its earnings as a dividend. ProMIS Neurosciences, Inc. pays out -- of its earnings as a dividend.

Lexaria Bioscience Corp. quarterly revenues are $174K, which are larger than ProMIS Neurosciences, Inc. quarterly revenues of --. Lexaria Bioscience Corp.'s net income of -$2.7M is higher than ProMIS Neurosciences, Inc.'s net income of -$11.6M. Notably, Lexaria Bioscience Corp.'s price-to-earnings ratio is -- while ProMIS Neurosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexaria Bioscience Corp. is 13.87x versus -- for ProMIS Neurosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals, Inc. has a net margin of -2178.51% compared to Lexaria Bioscience Corp.'s net margin of -867.29%. Lexaria Bioscience Corp.'s return on equity of -147.19% beat Xenon Pharmaceuticals, Inc.'s return on equity of -44.39%.

Lexaria Bioscience Corp. has a consensus price target of $4.50, signalling upside risk potential of 727.51%. On the other hand Xenon Pharmaceuticals, Inc. has an analysts' consensus of $55.40 which suggests that it could grow by 25.57%. Given that Lexaria Bioscience Corp. has higher upside potential than Xenon Pharmaceuticals, Inc., analysts believe Lexaria Bioscience Corp. is more attractive than Xenon Pharmaceuticals, Inc..

Lexaria Bioscience Corp. has a beta of 0.628, which suggesting that the stock is 37.221% less volatile than S&P 500. In comparison Xenon Pharmaceuticals, Inc. has a beta of 1.027, suggesting its more volatile than the S&P 500 by 2.689%.

Lexaria Bioscience Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexaria Bioscience Corp. pays -- of its earnings as a dividend. Xenon Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Lexaria Bioscience Corp. quarterly revenues are $174K, which are larger than Xenon Pharmaceuticals, Inc. quarterly revenues of --. Lexaria Bioscience Corp.'s net income of -$2.7M is higher than Xenon Pharmaceuticals, Inc.'s net income of -$90.9M. Notably, Lexaria Bioscience Corp.'s price-to-earnings ratio is -- while Xenon Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexaria Bioscience Corp. is 13.87x versus 463.67x for Xenon Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.